Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S, Seridi L, Chakravarty SD, Shawi M, Lavie F, Sharaf M, Zimmermann M, Kollmeier AP, Xu XL, Rahman P, Mease PJ, Deodhar A.
Siebert S, et al. Among authors: sharaf m.
Arthritis Rheumatol. 2024 Jan 22. doi: 10.1002/art.42803. Online ahead of print.
Arthritis Rheumatol. 2024.
PMID: 38253404